Behnoosh R Momin1, Paulo S Pinheiro2, Helena Carreira3, Chunyu Li1, Hannah K Weir1. 1. Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. Epidemiology and Biostatistics, University of Nevada at Las Vegas, Las Vegas, Nevada. 3. Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Abstract
BACKGROUND: Worldwide, liver cancer is a leading cause of death for both men and women. The number of Americans who are diagnosed with and die of liver cancer has been rising slowly each year. Using data from the CONCORD-2 study, this study examined population-based survival by state, race, and stage at diagnosis. METHODS: Data from 37 statewide registries, which covered 81% of the US population, for patients diagnosed during 2001-2009 were analyzed. Survival up to 5 years was adjusted for background mortality (net survival) with state- and race-specific life tables, and it was age-standardized with the International Cancer Survival Standard weights. RESULTS: Liver cancer was diagnosed overall more often at the localized stage, with blacks being more often diagnosed at distant and regional stages than whites. 5-year net survival was 12.2% in 2001-2003 and 14.8% in 2004-2009. Whites had higher survival than blacks in both calendar periods (11.7% vs 9.1% and 14.3% vs 11.4%, respectively). During 2004-2009, 5-year survival was 25.7% for localized-stage disease, 9.5% for regional-stage disease, and 3.5% for distant-stage disease. CONCLUSIONS: Some progress has occurred in survival for patients with liver cancer, but 5-year survival remains low, even for those diagnosed at the localized stage. Efforts directed at controlling well-established risk factors such as hepatitis B may have the greatest impact on reducing the burden of liver cancer in the United States. Cancer 2017;123:5059-78. Published 2017. This article is a U.S. Government work and is in the public domain in the USA. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
BACKGROUND: Worldwide, liver cancer is a leading cause of death for both men and women. The number of Americans who are diagnosed with and die of liver cancer has been rising slowly each year. Using data from the CONCORD-2 study, this study examined population-based survival by state, race, and stage at diagnosis. METHODS: Data from 37 statewide registries, which covered 81% of the US population, for patients diagnosed during 2001-2009 were analyzed. Survival up to 5 years was adjusted for background mortality (net survival) with state- and race-specific life tables, and it was age-standardized with the International Cancer Survival Standard weights. RESULTS:Liver cancer was diagnosed overall more often at the localized stage, with blacks being more often diagnosed at distant and regional stages than whites. 5-year net survival was 12.2% in 2001-2003 and 14.8% in 2004-2009. Whites had higher survival than blacks in both calendar periods (11.7% vs 9.1% and 14.3% vs 11.4%, respectively). During 2004-2009, 5-year survival was 25.7% for localized-stage disease, 9.5% for regional-stage disease, and 3.5% for distant-stage disease. CONCLUSIONS: Some progress has occurred in survival for patients with liver cancer, but 5-year survival remains low, even for those diagnosed at the localized stage. Efforts directed at controlling well-established risk factors such as hepatitis B may have the greatest impact on reducing the burden of liver cancer in the United States. Cancer 2017;123:5059-78. Published 2017. This article is a U.S. Government work and is in the public domain in the USA. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
Entities:
Keywords:
cancer registries; hepatitis; liver; population-based survival
Authors: Claudia Allemani; Rhea Harewood; Christopher J Johnson; Helena Carreira; Devon Spika; Audrey Bonaventure; Kevin Ward; Hannah K Weir; Michel P Coleman Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: S Kubo; K Hirohashi; H Tanaka; T Tsukamoto; T Shuto; T Ikebe; T Yamamoto; K Wakasa; S Nishiguchi; T Kuroki; H Kinoshita Journal: World J Surg Date: 2000-12 Impact factor: 3.352
Authors: S Kubo; K Hirohashi; H Tanaka; T Tsukamoto; T Shuto; T Yamamoto; T Ikebe; K Wakasa; S Nishiguchi; H Kinoshita Journal: Cancer Date: 2000-03-01 Impact factor: 6.860
Authors: Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman Journal: Lancet Date: 2014-11-26 Impact factor: 79.321
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Paulo S Pinheiro; Karen E Callahan; Francis P Boscoe; Raymond R Balise; Taylor R Cobb; David J Lee; Erin Kobetz Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-07-19 Impact factor: 4.254
Authors: Claudia Allemani; Rhea Harewood; Christopher J Johnson; Helena Carreira; Devon Spika; Audrey Bonaventure; Kevin Ward; Hannah K Weir; Michel P Coleman Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: Thomas B Richards; S Jane Henley; Mary C Puckett; Hannah K Weir; Bin Huang; Thomas C Tucker; Claudia Allemani Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: Meheret Endeshaw; Benjamin D Hallowell; Hilda Razzaghi; Virginia Senkomago; Matthew T McKenna; Mona Saraiya Journal: Cancer Date: 2018-11-27 Impact factor: 6.860